Vasculopathy
6
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
7 treatments under study, led by Alirocumab
Research Leaders
7 sponsors active, led by National Heart, Lung, and Blood Institute (NHLBI)
Related Conditions
Often studied with 4 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (6)
Cardiac Allograft Vasculopathy Inhibition With Alirocumab
Evaluation of Accelerated Sampling Techniques for Vessel Wall Imaging
Statin InTensity to Prevent Coronary Artery Vasculopathy After Heart Transplantation
The Role of CD34 + Stem Cells and Biomarkers in the Development of CAV in HTX Patients
Quantification of Elastin Markers Synthesis in Williams-Beuren Syndrome and 7q11.23 Micro-duplication Syndrome
Cardiac Allograft Vasculopathy and Dobutamine Stress Echocardiography / Brain Natriuretic Peptide Coupling
Research Network
Common Treatments
- Alirocumab1
- Physical Examination And Urine And Blood Samples1
- Atorvastatin1
- Urine And Blood Samples1
- Dobutamine Stress Echocardiography Coronarography Brachial Arterial Echography1
Active Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)1
- Stanford University1
- University Hospital, Strasbourg, France1
- University Medical Centre Ljubljana1
- University of Pennsylvania1
Top Investigators
Stanford University
Hôpitaux Universitaires de Strasbourg
Montefiore Medical Center
bojan.vrtovec@kclj.si
Advanced Heart Failure and Transplantation Center, Dept. of Cardiology, University Medical Center Ljubljana, Slovenia
Related Conditions
- Microduplication 7q1123 Syndrome1
- Heart Transplant Failure1
- Allograft1
- Williamsbeuren Syndrome1